Abstract
The significance of exosomes as intercellular messengers in a range of biological phenomena has hugely inspired many researchers to use them for disease diagnosis and treatment. Likewise, since the adoption of exosomes as new tools for our research, I aspired to address relevant delivery challenges with my expertise in the field of nanomedicine to develop better exosome-related therapies. In particular, innately therapeutic and exogenous drug-loaded exosomes should be located at the target site, whereas pathological exosomes or their biogenesis pathways should be targeted to control them. Reflecting recent preclinical efforts in my research group to meet such needs, the related previous work history, and initial accomplishments for regulating the in vivo fate of exosomes are covered in this contribution to the Orations-New Horizons of the Journal of Controlled Release, along with our ambitions for future developments in the field.
| Original language | English |
|---|---|
| Pages (from-to) | 483-488 |
| Number of pages | 6 |
| Journal | Journal of Controlled Release |
| Volume | 348 |
| DOIs | |
| State | Published - Aug 2022 |
Keywords
- Biogenesis inhibition
- Exosome
- Extracellular vesicle
- Nanomedicine
- Surface modification
- Targeting strategy
Fingerprint
Dive into the research topics of 'Regulation of in vivo fate of exosomes for therapeutic applications: New frontier in nanomedicines'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver